ICPT News and Press, Intercept Pharmaceuticals Inc. From 08/02/23

Ocaliva® (obeticholic acid or OCA) net sales of $83.7 million, representing 17% growth over the prior year quarter Company updates full-year 2023 Ocaliva net sales guidance to $320 million to $340 million; reiterates non-GAAP adjusted operating expense guidance of $350 million to $...

2023-08-01 11:17:37 ET Intercept Pharma ( NASDAQ: ICPT ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$0.46 (+32.4% Y/Y) and the consensus Revenue Estimate is $79.57M (+10.9% Y/Y). Over the la...

MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial res...

2023-07-13 17:30:00 ET Summary Madrigal Pharmaceuticals, Inc. dual surrogate Primary endpoint being met in phase 3 MAESTRO-NASH study allowed for the rolling NDA submission of resmetirom for the treatment of patients with NASH. Potential for rolling NDA submission of resmetirom to...

2023-07-13 08:04:34 ET Intercept Pharmaceuticals ( NASDAQ: ICPT ) gained ~10% pre-market Thursday after H.C. Wainwright upgraded it to Buy from Sell, citing a novel drug combination the company is developing for an autoimmune disease called primary biliary cholangitis (PBC). ...

2023-06-29 10:48:14 ET Viking Therapeutics ( NASDAQ: VKTX ) traded higher for the second straight session on Thursday after analysts defended the biotech following a selloff triggered by strong data from Eli Lilly’s ( LLY ) experimental drug retatrutide for non-alcoholic ...

2023-06-29 08:29:48 ET Eco Wave Power  ( WAVE ) +56% . RenovoRx ( RNXT ) +24% . Kintara Therapeutics ( KTRA ) +22% . Intelligent Living Application  ( ILAG ) +15% . Joby Aviation ( JOBY ) +14% rallies 10% to new 52-week h...

2023-06-23 12:03:39 ET Summary The FDA confirmed the news everybody had been expecting yesterday - Intercept's obeticholic acid ("OCA") was rejected for approval in NASH. Safety data evaluated by the agency failed to establish a positive risk/benefit profile and the drug was rejec...

2023-06-23 07:33:10 ET A day after the FDA rejected its lead asset, obeticholic acid (OCA) for nonalcoholic steatohepatitis (NASH), Intercept Pharmaceuticals ( NASDAQ: ICPT ) announced Friday that the company will halt all NASH-related investments and cut approximately a third of it...

Measures reinforce Company’s ability to drive growth in PBC business and continue developing innovative new medicines Company to discontinue all NASH-related investment and reduce workforce by approximately one third Company anticipates achieving profitability in 2024 ...